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Valproic acid (VPA)Phosphatidylinositol (3–5) trisphosphate (PIP3) is a central regulator of diverse neuronal functions that are critical
for seizure progression, however its role in seizures is unclear. We have recently hypothesised that valproic acid
(VPA), one of the most commonly used drugs for the treatment of epilepsy, may target PIP3 signalling as a
therapeutic mode of action. Here, we show that seizure induction using kainic acid in a rat in vivo epilepsy
model resulted in a decrease inhippocampal PIP3 levels and reducedprotein kinase B (PKB/AKT) phosphorylation,
measured using ELISA mass assays and Western blot analysis, and both changes were restored following VPA
treatment. These ﬁnding were reproduced in cultured rat hippocampal primary neurons and entorhinal cortex–
hippocampal slices during exposure to the GABA(A) receptor antagonist pentylenetetrazol (PTZ), which iswidely
used to generate seizures and seizure-like (paroxysmal) activity. Moreover, VPA's effect on paroxysmal activity in
the PTZ slice model is blocked by phosphatidylinositol 3-kinase (PI3K) inhibition or PIP2 sequestration by
neomycin, indicating that VPA's efﬁcacy is dependent upon PIP3 signalling. PIP3 depletion following PTZ treatment
may also provide a positive feedback loop, since enhancing PIP3 depletion increases, and conversely, reducing PIP3
dephosphorylation reduces paroxysmal activity and this effect is dependent upon AMPA receptor activation. Our
results therefore indicate that PIP3 depletion occurs with seizure activity, and that VPA functions to reverse these
effects, providing a novel mechanism for VPA in epilepsy treatment.
© 2013 The Authors. Published by Elsevier Inc.Open access under CC BY-NC-ND license. Introduction
Despite the emergence of many new antiepileptic drugs in the last
couple of decades (Bialer and White, 2010), approximately one-third
of all epilepsy patients continue to have poorly controlled seizures
(Kwan and Brodie, 2006). As a result, there has been considerable
interest in deﬁning the cellular and molecular changes in the brain
that contribute to the occurrence of spontaneous seizures and epilepsy
(Bialer et al., 2010). Understanding these will lead to therapeutic
strategies not only for controlling the development of epilepsy
(epileptogenesis) after a brain injury, but also for identifying new
targets for treating seizures.cal and Experimental Epilepsy,
, WC1N 3BG, UK.
iomedical Sciences, School of
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ect.com).
. Open access under CC BY-NC-ND licenThe phosphoinositide, phosphatidylinositol (3–5)-trisphosphate
(PIP3), contributes to cell signalling and has an important regulatory
role not only in acute cellular physiology (e.g. synaptic transmission)
but also in maintaining basal cellular activity (Vanhaesebroeck et al.,
2012). Phosphoinositide levels are controlled by a complex range of
lipid kinases and phosphatases (Andrews et al., 2007; Cantley, 2002;
Di and De, 2006; Wu and Hu, 2010). In the case of PIP3, the ﬁnal step
in its production is catalysed by phosphatidylinositol 3 kinase (PI3K)
and the cellular effects of PIP3 are inhibited by dephosphorylation
through phosphatases, including the SH2 domain-containing inositol
5′-phosphatase 2 (SHIP2) (Andrews et al., 2007; Suwa et al., 2009)
and the phosphatase and tensin homolog (PTEN). The cellular function
of PIP3 is mediated through direct binding to a wide range of proteins
and the downstream regulation of the protein kinase B (PKB or AKT)
signalling pathway (Andrews et al., 2007; Wu and Hu, 2010).
Several recent studies have implicated the PI3K/PIP3/AKT pathway
in seizure generation and epilepsy. The pro-apoptotic activity of the
Bcl-2 interacting mediator of cell death (Bim) pathway is regulated by
PIP3-dependent phosphorylation of AKT, which is upregulated after
seizures in animalmodels, and is altered in the hippocampus of patients
with intractable epilepsy (Shinoda et al., 2004). The mammalian target
of rapamycin (mTOR) pathway, which is a target of AKT and thus is
also activated by PIP3, plays an important role in epileptogenesis inse. 
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Lew, 2011; Zeng et al., 2009; Zhang and Wong, 2012). Finally, deletion
of PTEN in dentate granule cells results in spontaneous seizures and
abnormal electroencephalogram (EEG) activity (Backman et al., 2001;
Ljungberg et al., 2009). Therefore, PIP3 and the phosphoinositide
pathway in general, provide excellent candidate targets for regulating
ictogenesis and epileptogenesis.
VPA (valproic acid, 2-propylpentanoic acid) is a commonly used
broad-spectrum antiepileptic drug (Loscher, 1999) with multiple
mechanisms (Balding and Geller, 1981; Boeckeler et al., 2006; Chang
et al., 2010; Elphick et al., 2011; Lagace et al., 2005; Terbach and
Williams, 2009). A number of these mechanisms could be explained
by an action of VPA on phosphoinositides. We have recently shown
that VPA rapidly attenuates the turnover of phosphoinositides in a
simple biomedical model, Dictyostelium (Chang et al., 2012; Xu et al.,
2007), and this predicts seizure control activity in mammalian in vitro
seizure models (Chang et al., 2012, 2013). However, an established
role for VPA in regulating seizure-dependent phosphoinositide turnover
has yet to be established.
Here, we investigated the regulation of PIP3 in an in vivo kainic
acid induced seizure model, in an in vitro neuronal culture model for
PTZ-induced burst activity and in an in vitro model of induced
paroxysmal activity in ex-vivo slices using PTZ, using radio-labelled
inositol, PIP3 ELISA mass assays, and Western blot analysis. Using
these readouts, we show that PIP3 levels decrease in all these models
and that VPA restores PIP3 level, providing a novel mechanistic insight
into VPA function. We further show that modulating phosphoinositide
signalling regulates both paroxysmal activity and the efﬁcacy of VPA
in regulating these seizure-associated activities. Together our results
indicate that PIP3 depletion is a critical step in PTZ/kainic acid-induced
seizure progression and that VPA acts on this pathway, providing a
novel mechanistic target for seizure control.
Methods
Chemicals
All chemicals were provided by Sigma Pty Ltd (unless otherwise
stated).
Animals
Male Sprague–Dawley rats (SD) were kept under controlled envi-
ronmental conditions (24–25 °C; 50–60% humidity; 12 h light/dark
cycle) with free access to food and water. All the experiments were
approved by a local ethics committee, the UK home ofﬁce and
performed in accordance with the guidelines of the Animals (scientiﬁc
procedure) Act 1986.
Kainic acid treatment to induced status epilepticus
Male Sprague–Dawley rats (300–350 mg) were given kainic acid
(Tocris Biosciences) at a dose of 10mg/kg (Gupta et al., 2002), or saline
by intraperitoneal injection. Experimental animals were than
monitored to determine the severity of seizures. The rating of the
severity of seizures was based on the Racine scale (stage 1, mouth and
facial movements; stage 2, head nodding and more severe facial and
mouth movements; stage 3, forelimb clonus; stage 4, rearing and
bilateral forelimb clonuses; stage 5, rearing and falling, with loss
of postural control, full motor seizure) (Racine et al., 1972). Onset of
seizures occurred 30–100 min after kainic acid injection. One hour
after the animals reached stage 5 behavioural seizures, single doses
of either saline or VPA (400 mg/kg) were separately administered
intraperitoneally and 1 h after drug application, the animals were
sacriﬁced by being placed in a CO2 chamber (10 L volume chamber
with a ﬂow rate of 4 L/min). The hippocampi were then collected forfurther analysis, including PIP3 assay (using total protein as a loading
control) and Western blot analysis (as described below).
Western blot analysis
Brain tissue was homogenized by 10 up-and-down strokes of a
homogenizer in 10 times the brain tissue volume of aCSF (in mM:
NaCl 119, KCl 2.5, MgSO4 1.3, CaCl2 2.5, NaH2PO4 1, NaHCO3 26.2 and
glucose 16.6). After centrifugation, cells were washed with ice-cold
phosphate buffered saline (PBS), followed by lysis for 5min in ice-cold
RIPA Buffer supplemented with protease (Complete mini EDTA free,
Roche) and phosphatase inhibitors (PhosStop, Roche). Cell lysates
were centrifuged at 12,000 g for 5 min, and equal amounts of protein
supernatant (20 μg) were separated by 10% SDS-PAGE and transferred
onto PVDFmembrane (Immobilon ®-FL transfer membrane, Millipore).
Membranes were blocked with Tris-buffered saline–tween-20 (TBST)
containing 5% BSA and incubated with primary antibodies (AKT and
phospho-AKT(Ser473), Cell Signalling 587 F11) overnight at 4 °C. After
washing with TBST, membranes were incubated with secondary
antibodies (IRDye 800CW Goat anti-Rabbit and IRDye 800CW Goat
anti-Mouse, Odyssey) for 1 h at room temperature. After a second
round ofwashingwith TBST, the immuno-reactive bandswere visualized
using an Odyssey Infrared Imaging System.
PI(3–5)P3 ELISA mass assay
A PIP3 ELISA mass assay (Echelon Biosciences, Inc.) was used as an
independent means to determine the relative amount of PIP3 present
in treated or untreated neuronal cell cultures. For primary neuronal
cultures, tissue culture media were removed from cells and the
experiments were stopped by the addition of 0.5mL of ice-cold 0.5M
TCA. For hippocampal slice experiments, brain tissue was homogenized
in 10 times the brain tissue volume of aCSF by 10 up-and-down strokes
of a tissue homogenizer (Dounce tissue grinder). Lipid extraction was
carried out as described below, and for each condition, the PIP3 analysis
was carried out as described in themanufacturer's instructions,with the
colorimetric signal measured by a plate reader at 450nm.
Hippocampal neuronal cultures
Neuronal cultures were prepared from the hippocampi of P0–P3
postnatal rats. Brain dissection was performed in ice-cold dissection
solution (in mM: NaCl 137, 5.4 KCl, Na2HPO4 0.25, KH2PO4 0.44, CaCl2
1.3, MgSO4 1.0, NaHCO3 4.2, HEPES 5, and 20%FBS). The dissected tissue
was then incubated for 10 min in 0.25% (w/v) trypsin in 37 °C and
washed twice with washout solution (in mM: NaCl 137, KCl 5.4,
Na2HPO4 0.25, KH2PO4 0.44, CaCl2 1.3, MgSO4 1.0, NaHCO3 4.2, HEPES
5) and dissociated by trituration in the presence of DNase (150mg/mL).
Cells were then plated on poly-L-lysine-coated 12-well plates with
neurobasal A medium, containing supplement B27 (and 25 μM
glutamine), and AraC (1 μM) was added to the cultures within 48 h of
plating. The medium was changed once per week. Experiments were
carried out 14days after neuron cell preparation.
Cell radiolabelling and detection
Primary hippocampal cells in 12-well plates were labelled by addi-
tion of 0.1 μM myo-2-[3H]-inositol (20 Ci/mmol) (Hartmann Analytic
GmbH) to the medium overnight. Cells were then washed with
unlabelled medium prior experimentation. To analyse PTZ-induced
activity, cells were treated with 5 mM PTZ for 20 min (Sugaya et al.,
1989), followed by addition of drugs for 30 min. Following PTZ-
induction and drug treatment, the reactions were terminated by
replacing media with 500 μL of ice-cold 0.5 M trichloroacetic acid
(TCA), cells were then scraped, collected, and cell pellets were washed
twice with 5mL of 300 μM TCA containing 1mM EDTA.
298 P. Chang et al. / Neurobiology of Disease 62 (2014) 296–306Analysis of 3H-inositol distribution involved the extraction of
labelled cell pellets with 0.75 mL of chloroform/methanol/12 N
HCl (2/4/0.1, v/v). After thorough mixing, chloroform (0.25 mL) and
water (0.25 mL) were then added and vortexed. The samples were
centrifuged at a low speed for 20 min, with 100 μL of the resulting
aqueous phase and organic phase used for [3H]-inositol phosphate
and [3H]-inositol lipid, analysis respectively by scintillation counting.
The remaining lower organic phase containing the [3H]-inositol lipids
was also collected, dried under vacuum, and analysed by thin-layer
chromatography (TLC). Lipids were separated in: chloroform/acetone/
methanol/acetic acid/water (40/13/15/12/7 v/v), using TLC plates
(silica gel 60 (VWR Pty Ltd)), pretreated by coating with a mixture
of methanol/water (2/3 v/v) containing 1% potassium oxalate (w/v)
followed by dessication at 100 °C for 20–30 min before use.
Phosphoimaging plates (Fuji BAS-TR2040) were used to monitor
[3H]-inositol lipid distribution by at least 14 day exposure, prior to
visualization on a Typhoon phosphoimager. Individual lipid spots were
then quantiﬁed by liquid-scintillation (Beckman Pty Ltd). Authentic
standards were used for PIP2, PIP, and Pl, and the lipids were visualized
using 0.2% (w/v in methanol) 8-Anilino-1-naphthalenesulfonic acid
ammonium salt, or 10% cupric sulphate in 8% aqueous phosphoric
acid, allowed to dry 10min at room temperature, and then placed into
a 145 °C oven for 10min (Supplementary Fig. 1).
In vitro electrophysiology
The preparation of entorhinal cortex-hippocampus slices and electro-
physiological recording in CA1 has been described previously (Armand
et al., 1998; Chang et al., 2010). In brief, SD rats (P20–P30, 50–150 g)
were decapitated after killing by intraperitoneal injection with an
overdose of pentobarbitone (500 mg/kg). The brain was removed
and placed in oxygenated ice-cold sucrose solution (in mM: NaCl
87, KCl 2.5, MgCl2 7, CaCl2 0.5, NaH2PO4 1.25, NaHCO3 26.2, sucrose
75 and glucose 3). Slices (350 μm) were prepared with a Vibratome
(Vibratome® 1500 sectioning system, Intracell) and were then stored
in an interface chamber containing aCSF for at least 1 h. During the
experiment, slices were transferred from the interface chamber into a
submerged recording chamber and continuously perfused using gravity
feed at 3-6mL/min with prewarmed (36 °C) oxygenated aCSF (95% O2,
5% CO2). Field potentials were recorded with a glass microelectrode
(1–2 MΩ) ﬁlled with aCSF solution placed in stratum radiatum of
CA1 and were ﬁltered at 1 kHz and digitized at 2 kHz (using an npi
EXT-02 F extracellular ampliﬁer recorded with WinEDR software). To
induce epileptiform (paroxysmal) activity, PTZ (2 mM) was added to
the perfusate and [K+] was increased (to 6 mM). Once the frequency
of the paroxysmal activity was stable for at least 10 min, compounds
were applied to the perfusate for the following 40 min, and washed
out for a remaining 20min. The anticonvulsant effects were evaluated
by measuring the change in the frequency of the discharges at minute
intervals. The discharge frequency was then averaged every 5 min
during the experiment and normalised to baseline. The compounds
PI103 (Echelon Biosciences, Inc.), AS 1949490 (Tocris Bioscience Pty
Ltd), LY 294002 (Echelon Biosciences, Inc.), CNQX and kynurenic acid
were prepared as 1000 times stocks in dimethylsulfoxide (DMSO).
VPA was dissolved in distilled water as a 1000 times stock. Stocks
were dissolved in aCSF to achieve their ﬁnal concentrations during
experiments.
Data analysis
Results are presented as mean±SEM. Statistical comparisons were
performed by using the paired Student's t-test or one way ANOVA
followed by Tukey for post-hoc analysis for signiﬁcant main effects by
using GraphPad Prism. Statistical signiﬁcance was taken as follows:
∗pb0.05; ∗∗pb0.01, and ∗∗∗pb0.005.Results
An in vivo decrease in hippocampal pSer473 AKT and PIP3 levels in a kainic
acid-induced status epilepticus model is restored by VPA
To examine a role for PIP3 during seizure activity and following VPA
treatment, we ﬁrst employed an in vivo seizure model where status
epilepticus was induced using kainic acid. In these experiments,
repeated intraperitoneal injection of kainic acid (10 mg/kg) (Gupta
et al., 2002) was used until animals developed stage 5 behavioural
seizures, and animals were then administered with intraperitoneal
VPA (400 mg/kg) or saline control, and hippocampi were removed
after 1 h. As reported previously (Chang et al., 2013), VPA caused a
signiﬁcant reduction in behavioural seizure score, as described by the
Racine scale, in these experiments (Supplementary Fig. 2). We then
determined the effect of VPA on PIP3 levels in vivo, both usingWestern
analysis to monitor the phosphorylation state of AKT and by direct
monitoring of PIP3 levels using an ELISA mass assay technique.
Since PIP3 is critical for the recruitment of cytosolic AKT to the plasma
membrane, enabling Thr308 phosphorylation by phosphoinositide-
dependent kinase 1, and subsequent Ser473 phosphorylation by the
rapamycin insensitive mTORC2 complex (Alessi et al., 1997; Apsel
et al., 2008; Sarbassov et al., 2005; Stokoe et al., 1997), the phos-
phorylation state of AKT can be used as a readout for PIP3 levels
(Huang et al., 2011). To assess the phosphorylation state of AKT during
seizures and following VPA treatment, hippocampi were extracted
from animals and analysed by Western blot using total AKT and
pSer473 AKT antibodies (Figs. 1A, B). These experiments showed a
signiﬁcant decrease in AKT phosphorylation after seizure induction
(49.9 ± 9.3% of control, N = 4, p = 0.045)(Figs. 1A, B). Treatment of
animals during seizure activity with VPA restored AKT phosphorylation
to control levels (101.0±13.6% of control, N=4, p=0.005 compared
to kainic acid treatment only). However, VPA treatment in the absence
of convulsant did not signiﬁcantly alter AKT phosphorylation levels
(102.0±5.5% of control, N=3). These data suggest that seizure activity
causes a reduction in PIP3 levels and VPA acts to block this reduction.
We then conﬁrmed the accuracy of ourWestern analysis by directly
measuring hippocampal PIP3 levels using a PIP3 ELISA mass assay
technique (Fig. 1C). In these parallel experiments, PIP3 was extracted
from in vivo hippocampi samples of treated animals and analysed,
where we observed a signiﬁcant decrease in PIP3 after seizure induction
(69.1±6.5% of control, N=4, p=0.003) (Fig. 1C), consistent with the
decrease shown for phosphorylated AKT levels. Treatment of animals
during seizure activity with VPA also restored PIP3 to control levels
(111.0 ± 7.4% of control, N = 4, p = 0.005 compared to kainic acid
treatment only). VPA treatment in the absence of convulsant did not
signiﬁcantly alter PIP3 levels (98.5 ± 4.6% of control, N = 3). These
experiments indicate a decrease in vivo hippocampal PIP3 levels during
kainic acid-induced seizure activity that is restored by treatment with
VPA, but also indicate that VPA in the absence of such activity does
not change PIP3 levels. Interestingly, separation of data derived from
kainate animals treated with saline only injections (control) between
animals that continued to seize 1 h post-injection and those that
showed reduced seizure-like behaviour suggests that the reduction
in PIP3 levels is dependent on the presence of seizure activity
(Supplementary Fig. 3).
PIP3 levels decrease in hippocampal neurons during PTZ-induced activity
and are restored by VPA
In order to investigate the role of phosphoinositide turnover
generally in seizure progression and as a target for VPA, we then
employed an in vitro model of bursting activity, using PTZ applied
to cultured rat primary hippocampal neurons. In these experiments
we labelled the cultured rat primary hippocampal neurons with myo-
[3H]-inositol which is incorporated into phosphoinositides (PI, PIP,
Fig. 1. In vivo status epilepticus activity induced by kainic acid decreases Ser473 AKT
phosphorylation and PIP3 levels but these are restored by VPA. Animals were induced
to stage 5 (Racine) behavioural seizures using kainic acid (KA; 10 mg/kg), single doses
of either saline or VPA (400 mg/kg) were then administered intraperitoneally, and
hippocampi were extracted and analysed. (A) Western immunoblot assays were used to
determine levels of phosopho-Ser473 (pAKT) and total (tAKT) AKT protein during status
activity or following VPA treatment, and (B) summarised for control (non-induced;
N=3), control with VPA (N=3), kainic acid (N=4), and kainic acid with VPA (N=4)
treated animals, with pAKT normalised to tAKT levels. (C) Derived samples were also
analysed by direct PIP3 ELISA mass assay. Graphs show means ± SEM, with individual
data point illustrated. Statistical analysis was performed by post-hoc Tukey test, following
ANOVA (*p b 0.05, **p b 0.01, ***p b 0.001).
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phosphate, InsP3 (Fig. 2A). Phosphoinositides were quantiﬁed by
lipid extraction and separation by thin layer chromatography (TLC)
(Fig. 2B), using puriﬁed phosphoinositides as controls (Supplementary
Fig. 1). Phosphoinositide turnover in these experiments was deter-
mined by measuring the change of [3H]-labelled phosphoinositide
distribution following application of the convulsant PTZ (5 mM)
(Sugaya et al., 1989). Previous studies have shown that application of
PTZ induces bursting activity in primary cultured neurons, in a similar
manner to seizure-like activity in hippocampal slices or in vivo
(Sugaya et al., 1989). Repeating this approach,we observed a signiﬁcant
decrease in PIP3 after application of PTZ (62.8±3.8% of control, N=18,p = 0.001 compared to control) (Figs. 2B, C), whereas there was no
change in PI, PIP, and PIP2 levels, nor in cytosolic inositol phosphates
(Supplementary Fig. 4). Similar to the in vivo results, application of
VPA (1 mM; a physiologically relevant level commonly used in these
studies (Chang et al., 2012, 2013)), under burst-inducing conditions,
restored PIP3 levels to those of control (92.2±7.7% of control, N=15,
p=0.012 compared to PTZ) (Figs. 2B, C). However (as observed in the
in vivo experiments), application of VPA under control conditions
(in the absence of PTZ) did not change PIP3 levels (106.0 ± 11.7% of
control, N = 9) suggesting an effect of VPA on PIP3 levels only under
burst-inducing conditions.
We also repeated these experiments using the PIP3 ELISAmass assay
to conﬁrm the accuracy of our [3H]-labelling experiments. Here, we
reproduced the cultured rat primary hippocampal neuron experiments,
and exposed cells to PTZ (5 mM) in the presence or absence of VPA
(Fig. 2D). Consistent with the previous experiments, administration of
PTZ signiﬁcantly decreased PIP3 level (44.9 ± 8.7% of control, N = 4
independent experiments in triplicate, p=0.000, compared to control).
Application of VPA (1 mM) restored PIP3 levels (81.9 ± 10.23% of
control, N = 5 independent experiments in triplicate, p = 0.049),
whereas application of VPA (1 mM) in control conditions (in the
absence of PTZ) had no signiﬁcant effect on PIP3 level (93.0±12.4% of
control, N=5 independent experiments in triplicate). As a control we
conﬁrmed that inhibition of PI3K activity (using 10 μM LY294002)
(Lee et al., 2005; Workman et al., 2010) resulted in a large reduction
in PIP3 level (45.0 ± 6.9% of control, N = 3 independent experiments
in triplicate).
pSer473 AKT and PIP3 levels decrease in vitro in hippocampal slices during
PTZ-induced paroxysmal activity and are restored by VPA
We then correlated paroxysmal activitywith PIP3 levels in an in vitro
seizure model using ex vivo rat hippocampal slices treated with PTZ.
Paroxysmal activity in these slices was recorded by ﬁeld potential
monitoring and pSer473 AKT phosphorylation and PIP3 levels were
measured, pre- and post-VPA treatment. In these experiments, epi-
leptiform discharges (paroxysmal activity) appeared 10–30 min after
application of PTZ and increased extracellular [K+] (to 6mM) (Sugaya
et al., 1989) (Fig. 3A). Epileptiform discharges consisted of a positive
ﬁeld potential on which population spikes were superimposed. In this
model, VPA caused a small but signiﬁcant decrease in the frequency of
PTZ-induced epileptiform discharges, 20–40 min after application (to
76.5 ± 2.2% of baseline N= 5, control 99.8 ± 3.5% of baseline N= 5)
(Figs. 3B, C), as has been previously shown (Chang et al., 2012;
Heinemann et al., 1994). Changes in PIP3 levels in hippocampal slices
during seizure induction were then measured by Western blot
analysis using total AKT and pSer473 AKT antibodies, and by PIP3
ELISA mass (Figs. 3D, E). These experiments demonstrated that
application of PTZ signiﬁcantly decreased pAKT levels (49.3± 4.7% of
control, N = 5, p = 0.00, compared to control) with no signiﬁcant
change in total AKT levels (104.7± 5.7% of control, N= 5) (Fig. 3D).
Application of VPA (1 mM) to the slices during paroxysmal activity
induction partially restored pAKT levels (77.1 ± 8.6% of control,
N = 5, p = 0.012, compared to PTZ). Application of VPA (1 mM) in
control condition had no effect on pAKT and total AKT levels
(90.7 ± 4.7% of control, N = 5, 101.7 ± 6.3% of control, N = 5,
respectively), consistent with the PIP3 data that the effect of VPA was
only evident during paroxysmal activity. Using the ELISA mass assay
approach, these hippocampal slices showed a signiﬁcant decrease
in PIP3 (41.3 ± 7.4% of control, N = 13) under bursting conditions
(Fig. 3E). Application of VPA restored PIP3 levels to that of control
(88.9 ± 13.9% of control, N = 11). Furthermore, as shown in the
dissociated primary neurons in culture experiments, VPA did not
change the level of PIP3 under control conditions (91.91 ± 12.66% of
control, N = 9), conﬁrming that the effect of VPA on PIP3 was only
evident during paroxysmal activity.
Fig. 2. Seizure-inducing conditions in primary rat hippocampal neurons decrease PIP3 levels but this is restored by VPA. (A) Phosphoinositide synthesis and interconversion can be
monitored by the use of radio-labelled myo-inositol (MI) that is incorporated into phosphatidylinositol (PI), then phosphatidylinositol 4 phosphate (PIP) and phosphatidylinositol 4,5
bisphosphate (PIP2) by sequential phosphorylation of the inositol ring by 4′ kinases (PI4K) and 5′ kinases (PI5K), respectively. Red circles represent phosphates. PIP2 is cleaved by
phospholipase C (PLC) to produce aqueous inositol trisphosphate (IP3) or is phosphorylated by 3′ kinases (PI3K) to produce PIP3. (B) Example of phosphoinositide labelling in primary
hippocampal neurons under seizure-inducing conditions (PTZ at 5 mM), imaged following separation by TLC. (C) Comparison of level of PIP3 in primary hippocampal neurons under
control condition (N=18) and with VPA alone (1mM, N=9), or in seizure-inducing conditions in the absence (N=18) or presence of VPA (1mM, N=14) measured by quantiﬁcation
of TLC separatedphosphoinositides in comparisonwith standards (Supplementary Fig. 1). (D) Comparison of PIP3 level in primary hippocampal neurons under control conditions (control,
N = 7) or with VPA alone (N= 5), or in seizure-inducing conditions in the absence (N= 4) or presence of VPA (1 mM; N= 5), or in control condition with PI3K inhibitor (10 μM,
LY-294002, LY, N = 3) measured by PIP3 ELISA mass assay. Graphs show means ± SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey
test, following ANOVA (*p b 0.05, **p b 0.01, ***p b 0.001). Data for other inositol phosphate species are provided in Supplementary Fig. 4.
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Having reproduced these in vivo PIP3 regulatory effects in vitro,
we then asked if VPA's efﬁcacy at decreasing paroxysmal activity is
dependent on PIP3 regulation. To do this, we tested the efﬁcacy of VPA
on controlling paroxysmal activity following a reduction in PI3K activity
(using two PI3K inhibitors; PI-103 (Bechard et al., 2012) and LY294002
(Lee et al., 2005; Workman et al., 2010)), and following sequestration
of PIP2 by neomycin (Gabev et al., 1989; Haughey et al., 1999; Lee
et al., 2005). In these experiments, paroxysmal activity was induced
in hippocampal slices (as previously with PTZ and elevated K+) for
30minprior to exposure to PI-103 (10μM) for 50minwith a subsequent
stable baseline recording for over 20min, prior to the addition of VPA
for an additional 40 min (Fig. 4). In these experiments, VPA alone
signiﬁcantly decreased the frequency of epileptiform discharges (VPA
only: 76.5± 2.2% of baseline, N= 5, p= 0.002 compared to control).
However, in the presence of PI-103, VPA efﬁcacy against PTZ-induced
paroxysmal activity control was abolished (PI-103 + VPA: 109.8 ±
4.1% of baseline (PI-103 only), N = 4, p = 0.000 compared to VPA
only). Similar results were observed in the presence of LY294002(20 μM) (LY294002 + VPA: 97.8 ± 7.0% of baseline (LY294002 only),
N = 4, p = 0.008 compared to VPA only). We then repeated these
experiments with neomycin, a compound that sequesters PIP2 with a
high afﬁnity (Gabev et al., 1989) and thus reduces PIP3 production.
In these experiments, neomycin (100 μM) application also blocked
the paroxysmal activity control effect of VPA on the frequency of
epileptiform activity (98.3± 1.8% of baseline (neomycin only), N= 5,
p = 0.004 compared to VPA only). These results suggest that the
anticonvulsant effect of VPA is dependent on modulation of PIP3
signalling.
Inhibiting PIP3 production or dephosphorylation in hippocampal slices
alters burst discharges during PTZ treatment
We next asked whether changes in PIP3 levels altered seizure
progression. We tested the effect of the pharmacological reduction of
PIP3 levels using a speciﬁc class I PI3K inhibitor (PI-103) (Fig. 5A), in
inﬂuencing the burst discharges in the in vitro PTZ-induced paroxysmal
activity model. PI-103 is a pyridofuropyrimidine lead compound
(Hayakawa et al., 2006), showing speciﬁcity for class IAα, β, and δ
Fig. 3. Epileptiform activity in rat hippocampal slices decreases Ser473 AKT phosphorylation and PIP3 levels but these are restored by VPA. (A) Example trace recording of epileptiform
activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2mM, K+ 6mM) and (B) following addition of VPA (1mM). (C) Comparison of the mean frequency
of burst discharges in the presence or absence of VPA (1mM), expressed as a percentage of the baseline value (N=5). (D)Western immunoblot assays show levels of phosopho-Ser473
(pAKT) and total (tAKT) AKT protein during epileptiform activity in hippocampal slices with summary data (N=5) showing pAKT normalised to tAKT levels. Graphs showmeans±SEM
with individual data point illustrated. (E) Comparison of PIP3 level in the same hippocampal slices (control (N=15), VPA (1mM, N=9)), and in seizure condition in the absence (N=13),
or presence (N=11) of VPAmeasured by PIP3 ELISA mass assay. Graphs showmeans±SEM, with individual data point illustrated. Statistical analysis was performed by post-hoc Tukey
test, following ANOVA (**p b 0.01, ***p b 0.001). Quantiﬁcation of washout epileptiform activity is shown in Supplementary Fig. 5.
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improved speciﬁcity compared to other PI3K inhibitors such as
Wortmannin and LY294002 (Workman et al., 2010). Application of
PI-103 (10 μM) to hippocampal slices during PTZ treatment sig-
niﬁcantly increased the frequency of burst activity to 138.9 ± 5.1%
of baseline, N = 5 (DMSO control: 99.1 ± 3.0% of baseline, N = 4,
p=0.005, unpaired t-test) (Figs. 5A, B, C). Since PI-103 does not induce
increased burst discharges in the absence of PTZ, this suggests that a
reduction in PIP3 production during paroxysmal activity results in
enhanced paroxysmal activity.
Since reducing PIP3 levels enhanced paroxysmal activity, we then
examined the reverse relationship, by reducing PIP3 dephosphorylation
in this model using AS1949490, a selective SHIP2 (SH2 domain-
containing inositol 5′-phosphatase 2) inhibitor (Suwa et al., 2009)
(Fig. 5A). SHIP2 catalyzes the dephosphorylation of PIP3 to PIP2 and is
strongly expressed in the mammalian brain (Dyson et al., 2005).
Administration of AS1949490 (10 μM) to hippocampal slices following
treatment with PTZ signiﬁcantly suppressed the frequency of burst
discharges to 82.7 ± 2.8% of baseline (N = 5, p = 0.01 compared to
DMSO, unpaired t-test) (Figs. 5A, B, D). This result, in combination
with that shown for PI-103, supports a role for PIP3 in providing an
important protective role in paroxysmal activity associatedwith seizure
progression.AMPA receptor activity is necessary for PIP3 depletion
Together our data indicate a causal relationship between PIP3
depletion and paroxysmal activity (related to seizure progression),
and moreover, imply that VPA's action is dependent upon the PIP3
pathway. However, our data does not preclude a role for seizure activity
itself leading to depletion of PIP3, which then further enhances
the seizure activity as a positive feedback loop. To examine this, we
employed two glutamate receptor antagonists, kynurenic acid, which
is a broad-spectrum glutamate receptor antagonist (Perkins and
Stone, 1982; Stone andBurton, 1988), and CNQX,which is a competitive
AMPA/kainate receptor antagonist (Honore et al., 1988; Watkins et al.,
1990); both have been shown to attenuate seizures (Baraban et al.,
2005; Galvan et al., 2000; Godukhin et al., 2002) and are not expected
to regulate PIP3 levels. Again using the hippocampal slice/PTZ-induced
paroxysmal activity model, application of kynurenic acid (1 mM)
signiﬁcantly decreased the frequency of epileptiform discharges (Kyn:
67.4 ± 2.2% of baseline, N = 4, p = 0.01, compared to control)
(Figs. 6A, B), and CNQX (20 μM) almost abolished the frequency of
burst activity (2.0 ± 2.3% of baseline, N = 4, p = 0.00, compared to
control), 20–40 min after PTZ application. Analysis of PIP3 levels in
these hippocampal slice samples using the PIP3 ELISA mass assay
showed that kynurenic acid (1 mM) and CNQX (20 μM) treatment
Fig. 4. VPA control of epileptiform activity is PIP3-dependent. (A) Example trace recording of epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ
(PTZ 2mM, K+ 6mM)under control conditions (DMSO) andwith VPA (1mM); or (B)with VPA (1mM) after treatmentwith PI3K inhibitors (PI-103 (10μM); LY-294002 (LY, 20μM)) and
following sequestration of PIP2 with Neomycin (Neo, 100 μM) for 30 min. (C) Summary of PTZ-induced epileptiform discharge data for hippocampal slices with VPA treatment only
(control) or with prior application of PI-103 (N=4), LY-294002 (N=4), or Neomycin (N=5), where VPA was applied between 0 and 40min. (D) Comparison of the mean frequency
of epileptiform activity under different conditions, averaged from 20 to 40min post-treatment. Graphs showmeans±SEM, with individual data point illustrated. Statistical analysis was
performed by post-hoc Tukey test, following ANOVA (**p b 0.01, ***p b 0.001).
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ment (Fig. 6C). These results indicate that AMPA receptor activity
is necessary for paroxysmal activity progression and the consequent
reduction in PIP3 levels during this process.
Discussion
In the present study, we show that PIP3 levels decrease following
in vivo seizures induced with kainic acid and during application of the
convulsant PTZ in two in vitro models, and this reduction is restored
by the widely used anti-epileptic drug, VPA (Fig. 7). We show that the
mechanismof VPA's action is likely to bedependent upon the regulation
of PIP3, since blocking PIP3 production (with pharmacological inhibitors
or by sequestration of PIP2) blocks VPA-dependent epileptiform activity
control. Alterations in PIP3 levels are likely to have an important effect
on cell behaviour during seizures since we show PIP3 regulates down-
stream cell signalling in the PKB/AKT pathway. Seizure-dependent
PIP3 reduction is also likely to be involved in seizure progression, since
attenuating PIP3 production during PTZ-induced paroxysmal activity
causes increased epileptiform activity and reduced dephosphorylation
reduces this activity. Inhibiting paroxysmal activity through blocking
AMPA receptors prevents PIP3 depletion, indicating that the reduction
in PIP3 is not caused by PTZ, but rather by the generation of paroxysmal
(burst) activity. This leads to a paradigm inwhich seizure-like activity is
associated with a reduction in PIP3, giving rise to a positive feedback
ampliﬁcation of this activity. These data therefore implicate, for theﬁrst time, a reduction in PIP3 levels in neurons during paroxysmal
activity as a therapeutic target for seizure control.
One important corollary of the data described here is that VPA may
have speciﬁc effects only visible during seizure activity, as VPA did not
affect PIP3 levels under control conditions. This observation is consistent
with previous studies that show that VPA only affects frequency
facilitation of synaptic transmission in epileptic but not control animals
(Chang andWalker, 2011). The impact of this is that it may be essential
to employ seizure-inducing conditions in subsequent experiments to
identify the primary target(s) of current treatments and to develop
new therapies for seizure control.
As PIP3 is crucial for the regulation of neuron excitability viamultiple
mechanisms (Vanhaesebroeck et al., 2012), there are a range of means
bywhich a reduction in PIP3 could be involved in seizure activity. During
receptor-stimulated activation, PIP3 is asymmetrically distributed on the
plasma membrane and interacts with proteins involved in cytoskeleton
assembly and membrane fusion during regulated endocytosis and
exocytosis (Schmid, 1997; Spiliotis and Nelson, 2003), suggesting that
PIP3 plays an important role in neurotransmission, receptor trafﬁcking
and membrane repair. PIP3 is also crucial in the modulation of voltage-
gated calcium channels (Viard et al., 2004) and directly regulates
the inwardly rectifying ATP-sensitive K+ channels (MacGregor et al.,
2002). Increasing PIP3 production promotes translocation of ion channels
to the plasma membrane, including nonselective cation and calcium-
dependent potassium channels (Kanzaki et al., 1999; Lhuillier and
Dryer, 2002). Furthermore, PIP3 regulates AMPA receptor localization
Fig. 5. Epileptiform activity in rat hippocampal slices is regulated by PIP3. (A) Pharmacological regulation of PIP3 can be used to reduce the conversion of PIP2 into PIP3 via PI3K inhibition
(using PI-103) and to reduce the conversion of PIP3 to PIP2 by SHIP2 inhibition (using As1949490). Red circles represent phosphates on phosphoinositides. (B) Example trace recording of
epileptiform activity (burst discharges) in hippocampal slices induced by application of PTZ (PTZ 2mM, K+ 6mM) under control conditions (DMSO) and after inhibition of PI3K activity
(PI-103, 10 μM) or SHIP2 activity (As, As1949490 10 μM). (C) Summary of the effect of PI-103 (N=5) and (D) AS1949490 (N=5) in PTZ-induced burst discharges in comparison with
control (DMSO),where averaged data is presented from 20 to 40min post-treatment. Graphs showmeans±SEM,with individual data point illustrated. Statistical analysiswas performed
by unpaired Student's t-tests (*p b 0.05, ***p b 0.001). Quantiﬁcation of washout epileptiform activity is shown in Supplementary Fig. 6.
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depletion enhances mobility and dispersion of AMPA receptors in spines
and reduces presynaptic activity (Arendt et al., 2010). Seizure-induced
depletion of PIP3 would also interfere in homeostatic synaptic plasticity
that precisely maintains basal synaptic activity (Davis, 2006; Wang
et al., 2012). These wide and varied functions of PIP3 in neuronal and
synaptic function, together with our demonstrated seizure-dependent
reduction in PIP3, suggest that seizure activity fundamentally changes
neuronal function.
One downstream target of PIP3 is the AKT/mTOR pathway and as
such, PIP3 regulation is likely to play a major role in the function of
this pathway. Post-seizure, AKT activation has been widely shown to
be increased in both animal seizure models and in the hippocampi
of epileptic patients (Shinoda et al., 2004; Zhang and Wong, 2012).
Blocking pathway activation post-seizure also prevents further seizure
development, thus implicating a transient increase in the pathway
activation after seizures in promoting epileptogenesis (MacGregor et al.,
2002; Meikle et al., 2008; Zeng et al., 2009). Suppression of post-seizure
mTOR activation in other seizure models (kainate and pilocarpine) also
blocks pathologic changes such as mossy ﬁbre sprouting and synapse
formation (Buckmaster and Lew, 2011; Buckmaster et al., 2009; Zeng
et al., 2010) and spontaneous seizures (Zeng et al., 2010) implicating
this effect as a mechanism leading to chronic epilepsy. The effect of
VPA observed by us on the AKT/mTOR pathway is also supported by arange of other studies, including in vitro (Lamarre and Desrosiers,
2008; Wu and Shih, 2011) and in vivo studies (Bates et al., 2012).
Thus our data suggest that seizure activity may reduce AKT/mTOR
activation, which then increases post-seizure to cause pathogenic
changes and epileptogenesis, and that this initial decrease is blocked
by VPA thereby possibly reducing post-seizure pathway elevation. It
remains to be determined if this PIP3-dependent action contributes to
the neuroprotective action of VPA (Bolanos et al., 1998; Brandt et al.,
2006; Li and El Mallahk, 2000; Mora et al., 1999; Wilot et al., 2007).
A range of different models are used in epilepsy research, where
models often show different sensitivities to epilepsy treatments,
presumably due to different molecular mechanisms. In the in vitro
studies described here, we have employed PTZ, which is thought to
function through regulating GABA(A) signalling, to induce paroxysmal
activity associated with seizure progression (Huang et al., 2001), and
have shown that this induction mechanism causes a reduction in PIP3,
which is rescued by VPA. We have also induced status epilepticus
in vivo using kainic acid, where kainic acid functions as a speciﬁc agonist
for a class of glutamate receptors (kainate receptors) (Nadler, 1981),
and have again shown a decrease in PIP3 during seizure activity and
that this decrease is also rescued by VPA. These results thus suggest a
common reduction in PIP3 levels during seizure-like activity following
exposure to multiple independent convulsants. Subsequent studies
will be necessary to investigate thismechanism in other seizuremodels,
Fig. 6.Glutamate receptor inhibitors reduce epileptiform activity and restore PIP3 levels in rat hippocampal slices. (A) Example trace recording of epileptiform activity (burst discharges) in
hippocampal slices induced by application of PTZ (PTZ 2mM, K+ 6mM) followed by treatment with kynurenic acid (Kyn, 1mM), a board spectrum glutamate receptor inhibitor, or CNQX
(20 μM), an AMPA receptor inhibitor. (B) Comparison of the mean frequency of epileptiform activity induced by PTZ application (N= 5), or following kynurenic acid (N=4) or CNQX
(N=4) treatment expressed as a percentage of the baseline value. (C) Comparison of PIP3 level in the same hippocampal slices following seizure induction with PTZ (N=5) or following
kynurenic acid (N=5) orCNQX(N=5) treatmentmeasuredbyPIP3 ELISAmass assay. Graphs showmeans±SEMwith individual data point illustrated. Statistical analysiswasperformed
by post-hoc Tukey test, following ANOVA (**p b 0.01, ***p b 0.001). Quantiﬁcation of washout epileptiform activity is shown in Supplementary Fig. 7.
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effect of VPA (Bolanos et al., 1998; Brandt et al., 2006).
VPA provides a range of therapeutic roles in addition to seizure
control, including bipolar disorder and migraine prophylaxis (Terbach
and Williams, 2009). It is currently unclear if the mechanism of action
for VPA identiﬁed here is common to these conditions. Recent studiesFig. 7. Action of valproic acid (VPA) in regulating PIP3 during seizure activity.
Phosphoinositide signalling (black) involves the phosphorylation of PIP2 to produce PIP3
by PI3K activity, and where the reverse reaction is catalysed by SHIP2 activity. PIP3
functions to regulate a range of cellular effects including the activation of downstream
AKT activity (blue) by phosphorylation. Seizure activity (green) triggers a decrease in
PIP3 giving rise to a feed-back ampliﬁcation effect. VPA functions to attenuate the
seizure-dependent decrease in PIP3 causing a resultant reduction in seizure activity.in a simple biomedical model system (Chang et al., 2012; Xu et al.,
2007) suggest that a VPA-dependent attenuation of phosphoinositides
is not associated with a decrease in cytosolic inositol levels. This site of
action contrasts with the function of VPA in bipolar disorder treatment
(Eickholt et al., 2005) where VPA is thought to act through a cytosolic
mechanism in the depletion of inositol phosphates (Berridge et al.,
1989; Terbach and Williams, 2009), possibly through the indirect
inhibition of de novo inositol synthesis (Eickholt et al., 2005; Shaltiel
et al., 2007; Vaden et al., 2001).
We have therefore shown for the ﬁrst time an effect of seizure
activity on PIP3 levels and that restoring these levels may have an
anti-seizure effect. Moreover, targeting this pathway with VPA reduces
paroxysmal activity. These ﬁndings suggest a novel approach to the
treatment of seizures and potentially other conditions for which VPA
is effective such as migraine and bipolar disorder.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2013.10.017.
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